Lapphra Keswadee, Vanprapar Nirun, Chearskul Sanay, Phongsamart Wanatpreeya, Chearskul Pimpanada, Prasitsuebsai Wasana, Chokephaibulkit Kulkanya
Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Int J Infect Dis. 2008 Nov;12(6):e33-8. doi: 10.1016/j.ijid.2007.10.008. Epub 2008 Jun 24.
Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based highly active antiretroviral therapy (HAART) has been the most affordable regimen for the HIV-infected in developing countries. There are limited data comparing nevirapine (NVP) to efavirenz (EFV) in HIV-infected children. This study aimed to assess the efficacy and tolerability of NVP-based regimens compared to EFV-based regimens in HIV-infected children in Thailand.
The medical records of HIV-infected children who had received NNRTI-based regimens for more than 6 months at the Department of Pediatrics, Siriraj Hospital, Mahidol University, Thailand, were reviewed.
Of the 139 HIV-infected children studied, 70 were male, and the median age at treatment initiation was 6.08 years (range 0.32-14.56 years); the median duration of follow-up was 36 months (range 6-66 months). The median baseline CD4 cell count was 185cells/mm(3) (range 2-3482cells/mm(3)) and the median baseline CD4 percentage was 7.20% (range 0.11-36.57%). An NVP-based regimen was initiated in 61 (44%): 38 antiretroviral (ARV)-naïve and 23 ARV-experienced. An EFV-based regimen was initiated in 78 (56%): 34 ARV-naïve and 44 ARV-experienced. The CD4 cell count and percentage gains were not different between the NVP and EFV groups in both the ARV-naïve and the ARV-experienced. However, ARV-naïve children who received an EFV regimen had significantly lower baseline CD4 levels than those who received an NVP regimen. ARV-naïve children had a better CD4 response than the ARV-experienced. The survival rates of children in the NVP groups were not different from those in the EFV groups for both the ARV-naïve and the ARV-experienced. Treatment failure occurred in one ARV-naïve NVP case (2.6%), two ARV-naïve EFV cases (5.8%), and nine ARV-experienced NVP cases (39%) at 24 months of treatment, and 11 ARV-experienced EFV cases (25%) at 18 months of treatment. Seven (10%) children had adverse effects from treatment with NVP. The main side effects were rash and hepatitis; six had to switch to EFV. Four (5%) children had adverse effects from treatment with EFV; two had to switch to NVP.
Both NVP- and EFV-based HAART regimens were effective in children in Thailand for at least 3 years. HIV-infected Thai children generally tolerated NNRTI well.
基于非核苷类逆转录酶抑制剂(NNRTI)的高效抗逆转录病毒疗法(HAART)一直是发展中国家艾滋病毒感染者最经济实惠的治疗方案。关于艾滋病毒感染儿童中奈韦拉平(NVP)与依非韦伦(EFV)对比的数据有限。本研究旨在评估在泰国艾滋病毒感染儿童中,基于NVP的治疗方案与基于EFV的治疗方案的疗效和耐受性。
回顾了泰国玛希隆大学诗里拉吉医院儿科接受基于NNRTI治疗方案超过6个月的艾滋病毒感染儿童的病历。
在研究的139名艾滋病毒感染儿童中,70名是男性,开始治疗时的中位年龄为6.08岁(范围0.32 - 14.56岁);中位随访时间为36个月(范围6 - 66个月)。基线CD4细胞计数中位数为185个细胞/mm³(范围2 - 3482个细胞/mm³),基线CD4百分比中位数为7.20%(范围0.11 - 36.57%)。61名(44%)儿童开始采用基于NVP的治疗方案:38名初治抗逆转录病毒(ARV)儿童和23名经治ARV儿童。78名(56%)儿童开始采用基于EFV的治疗方案:34名初治ARV儿童和44名经治ARV儿童。在初治和经治的ARV儿童中,NVP组和EFV组的CD4细胞计数和百分比增加情况无差异。然而,接受EFV治疗方案的初治儿童基线CD4水平显著低于接受NVP治疗方案的儿童。初治儿童的CD4反应优于经治儿童。对于初治和经治儿童,NVP组儿童的生存率与EFV组儿童无差异。在治疗24个月时,1例初治NVP病例(2.6%)、2例初治EFV病例(5.8%)以及9例经治NVP病例(39%)出现治疗失败;在治疗18个月时,11例经治EFV病例(25%)出现治疗失败。7名(10%)儿童在接受NVP治疗时有不良反应。主要副作用是皮疹和肝炎;6名儿童不得不改用EFV。4名(5%)儿童在接受EFV治疗时有不良反应;2名儿童不得不改用NVP。
基于NVP和EFV的HAART治疗方案在泰国儿童中至少3年有效。泰国艾滋病毒感染儿童对NNRTI总体耐受性良好。